Vaccines and therapeutics for immunocompromised patients with COVID-19
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …
This diverse group is at increased risk for impaired vaccine responses, progression to …
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
F Zhao, X Zai, Z Zhang, J Xu, W Chen - npj Vaccines, 2022 - nature.com
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had
become a global concern because of its unexpectedly high pathogenicity and …
become a global concern because of its unexpectedly high pathogenicity and …
[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …
due to altered antibody evasion properties deriving from their additional spike mutations …
Resistance of Omicron subvariants BA. 2.75. 2, BA. 4.6, and BQ. 1.1 to neutralizing antibodies
Convergent evolution of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 lineages has led to
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
the emergence of several new subvariants, including BA. 2.75. 2, BA. 4.6. and BQ. 1.1. The …
Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages have
escaped most receptor-binding domain (RBD)-targeting therapeutic neutralizing antibodies …
escaped most receptor-binding domain (RBD)-targeting therapeutic neutralizing antibodies …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults
Y Cai, S Diallo, K Rosenthal, K Ren, DJ Flores… - Science Translational …, 2024 - science.org
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
resulted in variants that can escape neutralization by therapeutic antibodies. Here, we …
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
L Wang, M Møhlenberg, P Wang, H Zhou - Cytokine & growth factor …, 2023 - Elsevier
Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has …
(SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has …
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that
has caused the recent coronavirus disease (COVID-19) global pandemic. The current …
has caused the recent coronavirus disease (COVID-19) global pandemic. The current …
A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment
D Focosi, A Casadevall - Viruses, 2022 - mdpi.com
Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …